Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CollPlant Biotechnologies (CLGN) Research & Development (2017 - 2025)

CollPlant Biotechnologies filings provide 9 years of Research & Development readings, the most recent being $2.0 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 22.14% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.2 million, a 22.14% decrease, with the full-year FY2025 number at $8.2 million, down 22.14% from a year prior.
  • Research & Development hit $2.0 million in Q4 2025 for CollPlant Biotechnologies, down from $2.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.1 million in Q4 2023 to a low of $1.6 million in Q1 2021.
  • Median Research & Development over the past 5 years was $2.3 million (2022), compared with a mean of $2.4 million.
  • The widest YoY moves for Research & Development: up 101.6% in 2021, down 99.79% in 2021.
  • CollPlant Biotechnologies' Research & Development stood at $2.2 million in 2021, then rose by 20.47% to $2.6 million in 2022, then increased by 18.05% to $3.1 million in 2023, then fell by 18.31% to $2.5 million in 2024, then decreased by 22.14% to $2.0 million in 2025.
  • The last three reported values for Research & Development were $2.0 million (Q4 2025), $2.1 million (Q3 2025), and $2.0 million (Q2 2025) per Business Quant data.